Loading market dashboard
Simulations Plus, Inc.
SLPHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters.
RBC Capital Markets has initiated coverage of Sylvania Platinum (AIM:SLP), the AIM-listed platinum group metals producer, with an Outperform rating and a price target of 175p, implying 90% upside from the current share price of 92p. The bank's investment case centres on what it describes as a systematic mispricing of the stock, which trades at 0.6x net asset value and a 20% free cash flow yield on 2027 estimates, valuations it says are more consistent with a distressed junior than a high-margin, cash-generative business.
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws.
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
San Diego, California--(Newsfile Corp. - June 3, 2026) - Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws after the Company reduced its fiscal 2025 revenue outlook, reported a significant impairment charge, and disclosed an auditor dispute involving segment reporting, reporting-unit determinations, and internal control over financial reporting. What if I purchased Simulations Plus securities?
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries.
SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries.
SAN DIEGO--(BUSINESS WIRE)---- $SLP #AuditorDispute--Johnson Fistel, PLLP is investigating potential claims on behalf of Simulations Plus, Inc. (NASDAQ: SLP) investors concerning whether the Company or certain of its executive officers violated federal securities laws.The Simulations Plus investigation focuses on investor losses following the Company's revised fiscal 2025 revenue outlook, reported impairment charge, auditor dismissal, and disclosures concerning segment reporting, reporting-unit determinations, and inter.
SAN DIEGO--(BUSINESS WIRE)---- $SLP #Inc--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries. On June 11, 2025, Simulations Plus announced preliminary third-quarter fiscal 2025 revenue and updated its full-year fiscal 2025 rev.
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in Minneapolis, Minnesota. Mr. O'Connor will host one-on-one meetings with institutional investors on Thurs.
Simulations Plus, Inc. (NASDAQ:SLP) shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp (NASDAQ:NVDA), aimed at enhancing GPU-accelerated simulation and AI-assisted workflows in drug development.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu.
CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.
Simulations Plus, Inc. (NASDAQ: SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry's future workforce. More than 1,400 scientists.
Simulations Plus, Inc. remains a Hold as business improvement is insufficient to warrant a Buy, despite stabilization post-earnings. Q2 2026 revenue grew 8% YoY to $24.3M, with strong software renewals (91%) and expanding services backlog (+18% YoY). SLP trades at ~14x blended earnings, appearing cheap versus history but still expensive on GAAP metrics given slow revenue and cash flow growth.
Smith Micro Software (NASDAQ: SMSI - Get Free Report) and Simulations Plus (NASDAQ: SLP - Get Free Report) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Volatility and Risk Smith
Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position.
It notched beats on both revenue and profitability in its fiscal second quarter. On a negative note, it cut its net income forecast for the full fiscal year.
SLP beats fiscal Q2 earnings and posts solid revenue growth, but cuts full-year EPS view even as backlog rises and margins expand across software and services.
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, repres.
JPMorgan Chase and Co. boosted its stake in shares of Simulations Plus, Inc. (NASDAQ: SLP) by 154.7% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 167,646 shares of the technology company's stock after purchasing an additional 101,822 shares during the period. JPMorgan Chase and Co.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how n.
